Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01670500 · ClinicalTrials.gov registry record · Phase 2
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT01670500 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 118 participants.
The verdict
NCT01670500, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug, which is cisplatin in this trial, to learn how well it works in treating a specific cancer. "Investigational" means that cisplatin is still being studied for use in this setting and that research doctors are trying to find out more about it-in this case, how effective cisplatin is for treating breast cancer in BRCA mutation carriers. It also means that the FDA has not yet approved cisplatin for your type of cancer. Cisplatin has been approved by the FDA for treatment of other cancers. The purpose of this study is to evaluate cisplatin, a chemotherapy drug that has been shown to be active in the treatment of women with breast cancer and a BRCA mutation. In this study, we are comparing cisplatin to the standard chemotherapy, doxorubicin and cyclophosphamide ("AC") that you might receive if you did not participate in this study.
Interventions
- DRUG Cyclophosphamide
- DRUG Cisplatin
- DRUG Doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2012-10 |
| Est. Completion | 2025-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01670500
The ClinicalTrials.gov registry entry for NCT01670500 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT01670500 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01670500 about?
NCT01670500 is a clinical study titled "Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa". This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug, which is cisplatin in this trial, to learn how well it works in treating a specific cancer. "Investigational" means that cisplatin is still being studied for use in this sett...
What is the current status of trial NCT01670500?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2012-10. Estimated completion is 2025-02-02.
What interventions are being tested in trial NCT01670500?
The interventions under investigation include: Cyclophosphamide (DRUG), Cisplatin (DRUG), Doxorubicin (DRUG).
Who is sponsoring clinical trial NCT01670500?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.